Trial Profile
A Randomized, Double-Blind and Placebo-Controlled Phase I Study to Evaluate the Safety and Primary Immunogenicity of the 9-valent Human Papillomavirus (Types 6, 11, 16, 18,31,33,45,52 and 58) Recombinant Vaccine (Hansenula Polymorpha) in Chinese Female Subjects Aged 9-45 Years
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 28 Jan 2020
Price :
$35
*
At a glance
- Drugs Human papillomavirus recombinant vaccine nonavalent - Shanghai Bovax Biotechnology (Primary)
- Indications Human papillomavirus infections
- Focus Adverse reactions
- Sponsors Shanghai Bovax Biotechnology
- 20 Jan 2020 Status changed from active, no longer recruiting to completed.
- 19 Sep 2019 Planned End Date changed from 8 Oct 2019 to 8 Nov 2019.
- 19 Sep 2019 Status changed to active, no longer recruiting.